🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 36870H103
- IPO
- 1/26/2023 · $6.00/share
Business: Genelux Corp is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The core of Genelux's discovery and development efforts revolves around the Company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
Company Contact
- CEO
- Thomas Zindrick
- CFO
- Lourie Zak
- Headquarters
- 2625 Townsgate Road, Suite 230, Westlake Village, CA 91361
- Phone
- 805-267-9889
- Investor Relations
- Ankit Bhargava, Allele Communications, LLC · 815-721-4912 · Genelux@allelecomms.com